比亚迪股份-R(81211)、中国海洋石油-R(80883)、美团-WR(83690)上一交易日沽空比率位于前三位，分 别为96.88%、80.42%、75.34%。美团-W(03690)、阿里巴巴-SW(09988)、快手-W(01024)的沽空金额位 居前三，分别为34.76 亿元、25.06 亿元、13.74 亿元。万科企业(02202)、中国海洋石油-R(80883)、比亚 迪股份-R(81211)的偏离值位居前三，分别为36.01%、35.40%、26.18%。 前十大沽空比率排行 | 股票名称 | 沽空金额 | 沽空比率↓ | 偏离值 | | --- | --- | --- | --- | | 比亚迪股份-R(81211) | 496.68 万元 | 96.88% | 26.18% | | 中国海洋石油-R(80883) | 57.37 万元 | 80.42% | 35.40% | | 美团-WR(83690) | 715.97 万元 | 75.34% | 15.02% | | 商汤-WR(80020) | 88.77 万元 | 66.55% | 13.10% | | 阿里巴巴-SWR(89988 ...

7月31日恒生指数下跌1.60%，南向资金全天合计成交金额为1704.75亿港元，其中，买入成交918.01亿 港元，卖出成交786.75亿港元，合计净买入金额131.26亿港元。具体来看，港股通（深）累计成交金额 616.04亿港元，买入成交335.63亿港元，卖出成交280.41亿港元，合计净买入金额55.22亿港元；港股通 （沪）累计成交金额1088.71亿港元，买入成交582.38亿港元，卖出成交506.34亿港元，合计净买入金额 76.04亿港元。 从连续性进行统计， 有3只股获南向资金连续3天以上净买入，连续净买入天数较多的有腾讯控股、阿 里巴巴-W、小米集团-W，连续净买入天数分别为6天、5天、5天。以其间净买入金额统计，净买入金 额最多的是小米集团-W，合计净买入为30.37亿港元，其次是腾讯控股合计净买入为27.05亿港元，阿里 巴巴-W合计净买入为26.73亿港元。 7月31日南向资金成交活跃股 | 代码 | 简称 | 成交金额（万港元） | 成交净买入（万港元） | 今日涨跌幅（%） | | --- | --- | --- | --- | --- | | 02800 | 盈富基金 | 2 ...

净买入盈富基金24.05亿、恒生中国企业17.82亿、美团-W 13.98亿、快手-W 13.83亿、阿里巴巴-W 10.43 亿、南方恒生科技9.73亿、小米集团-W 4.41亿、腾讯控股4.33亿、中芯国际2.21亿； 格隆汇7月31日｜南下资金今日净买入港股131.26亿港元。其中： 净卖出老铺黄金2.78亿、石药集团1.13亿。 据统计，南下资金已连续6日净买入腾讯，共计27.055亿港元；连续5日净买入阿里巴巴，共计26.7318亿 港元；连续5日净买入小米，共计30.3639亿港元。(格隆汇) ...

Core Insights - On July 31, 2025, Meituan-W (03690), Alibaba-W (09988), and Xiaomi Group-W (01810) were the top three companies by trading volume in the southbound section of the Hong Kong Stock Connect, with trading amounts of 4.049 billion, 3.790 billion, and 3.694 billion respectively [1][2] - In the southbound section of the Shenzhen-Hong Kong Stock Connect, Xiaomi Group-W (01810), Meituan-W (03690), and Tencent Holdings (00700) led the trading volume, with amounts of 2.438 billion, 2.300 billion, and 2.086 billion respectively [1][2] Southbound Trading Activity - The top three active companies in the southbound section of the Hong Kong Stock Connect were: - Meituan-W (03690) with a trading amount of 4.049 billion and a net buying amount of +1.196 billion - Alibaba-W (09988) with a trading amount of 3.790 billion and a net buying amount of +0.654 billion - Xiaomi Group-W (01810) with a trading amount of 3.694 billion and a net buying amount of +0.368 billion [2] - The top three active companies in the southbound section of the Shenzhen-Hong Kong Stock Connect were: - Xiaomi Group-W (01810) with a trading amount of 2.438 billion and a net buying amount of +0.736 billion - Meituan-W (03690) with a trading amount of 2.300 billion and a net buying amount of +0.202 billion - Tencent Holdings (00700) with a trading amount of 2.086 billion and a net buying amount of +0.336 billion [2]

Group 1: Market Overview - On July 31, the Hong Kong stock market saw a net inflow of 13.126 billion HKD from northbound trading, with 7.604 billion HKD from the Shanghai Stock Connect and 5.522 billion HKD from the Shenzhen Stock Connect [2] - The most bought stocks included the Tracker Fund of Hong Kong (02800), Hang Seng China Enterprises (02828), and Meituan-W (03690) [2][3] - The most sold stocks were Laopuhuangjin (06181), CSPC Pharmaceutical Group (01093), and Shandong Molong Petroleum Machinery (00568) [2] Group 2: Active Stocks - The top net bought stocks included Meituan-W (03690) with 2.622 billion HKD, Alibaba-W (09988) with 2.222 billion HKD, and Xiaomi Group-W (01810) with 2.031 billion HKD [3] - The top net sold stocks included Shandong Molong (00568) with 940 million HKD and CSPC Pharmaceutical Group (01093) with 891 million HKD [3] Group 3: ETF and Sector Insights - Northbound trading showed strong interest in ETFs, with the Tracker Fund of Hong Kong (02800) receiving a net inflow of 2.405 billion HKD, Hang Seng China Enterprises (02828) with 1.781 billion HKD, and Southern Hang Seng Technology (03033) with 973 million HKD [6] - The technology sector is highlighted as a significant part of the Hong Kong market, accounting for nearly one-third, with a focus on potential revaluation driven by technology [6] Group 4: Company-Specific News - Meituan-W (03690) received a net inflow of 13.98 billion HKD, while Kuaishou-W (01024) and Alibaba-W (09988) received 13.82 billion HKD and 10.43 billion HKD respectively [6] - Semiconductor company SMIC (00981) saw a net inflow of 2.21 billion HKD amid concerns regarding Nvidia's chip security issues [7] - Meitu Company (01357) received a net inflow of 15.3 million HKD, with Morgan Stanley raising its target price by 140% [7] Group 5: Performance Expectations - Laopuhuangjin (06181) faced a net outflow of 2.78 billion HKD, with analysts questioning the sustainability of its profit growth [8] - Analysts expect Laopuhuangjin's revenue to grow by 26% year-on-year next year, with adjusted net profit expected to rise by 30% [8] - Xiaomi Group-W (01810) received a net inflow of 441 million HKD, while CSPC Pharmaceutical Group (01093) and Shandong Molong (00568) faced net outflows [8]

Group 1 - The core point of the news is that the Hong Kong stock market saw significant net inflows from Northbound trading, with a total net buy of HKD 131.26 billion on July 31, 2023, indicating strong investor interest in certain stocks [1] - The most actively bought stocks included the Tracker Fund of Hong Kong (02800), Hang Seng China Enterprises (02828), and Meituan-W (03690), while the most sold stocks were Laopuhuangjin (06181), CSPC Pharmaceutical Group (01093), and Shandong Molong (00568) [1][2] - The Northbound trading saw net purchases of HKD 76.04 billion through the Shanghai Stock Connect and HKD 55.22 billion through the Shenzhen Stock Connect [1] Group 2 - The Tracker Fund of Hong Kong (02800) received a net buy of HKD 24.05 billion, while Hang Seng China Enterprises (02828) and Southern Hang Seng Technology (03033) received net buys of HKD 17.81 billion and HKD 9.73 billion, respectively [5] - Meituan-W (03690) and Kuaishou-W (01024) were also popular among investors, with net buys of HKD 13.98 billion and HKD 13.82 billion, respectively [5] - Semiconductor company SMIC (00981) received a net buy of HKD 2.21 billion, while Meituan (01357) saw a net buy of HKD 15.3 million, following a significant target price increase by Morgan Stanley [6] Group 3 - Laopuhuangjin (06181) faced a net sell of HKD 2.78 billion, with concerns about the sustainability of its profit growth [7] - Xiaomi Group-W (01810) received a net buy of HKD 4.41 billion, while CSPC Pharmaceutical Group (01093) and Shandong Molong (00568) experienced net sells of HKD 1.13 billion and HKD 371 million, respectively [7]

Group 1 - The innovative drug sector is experiencing significant activity, with multiple stocks, including Nanjing New Pharmaceutical and Qizheng Tibetan Medicine, hitting the daily limit up [1] - The focus of the market is on the major collaboration between Shijiazhuang Pharmaceutical Group and US biopharmaceutical company Madrigal Pharmaceuticals, involving the global rights transfer of the oral GLP-1 receptor agonist SYH2086 [1] - Shijiazhuang Pharmaceutical Group will receive a total transaction value of up to $2.075 billion, including an upfront payment of $120 million and potential milestone payments of up to $1.955 billion [1] Group 2 - The overall performance of pharmaceutical stocks is strong, with several stocks, including Nanjing New Pharmaceutical and Qizheng Tibetan Medicine, reaching the daily limit up [1] - In terms of market dynamics, the pharmaceutical and biological sector has a notable presence, with 7 out of 35 stocks hitting the daily limit up, indicating strong investor interest [2] - The innovative drug-related stocks are favored by market funds, with significant net inflows observed in the telecommunications equipment sector, amounting to 2.432 billion yuan [2]

Core Viewpoint - The company has entered into significant strategic agreements with multinational pharmaceutical companies, indicating strong growth potential and collaboration in drug development [1] Group 1: Strategic Partnerships - The company has signed a strategic research collaboration agreement with AstraZeneca worth up to $5.3 billion [1] - A new exclusive licensing agreement has been established with biopharmaceutical company Madrigal, potentially worth up to $2.075 billion [1] Group 2: Product Development - The exclusive licensing agreement with Madrigal pertains to the oral small molecule GLP-1 receptor agonist SYH2086 for global development, production, and commercialization [1] - The company retains rights to develop and sell other oral small molecule GLP-1 receptor agonist products in China [1] Group 3: Financial Terms - The agreement with Madrigal includes a total potential payment of up to $2.075 billion, comprising $120 million in upfront payments and up to $1.955 billion in potential development, regulatory, and commercial milestone payments [1] - Additionally, the company is entitled to receive a high double-digit sales royalty based on annual net sales of SYH2086 [1]

智通财经获悉，石药集团(01093)涨超5%，截至发稿，涨5.15%，报10.62港元，成交额6.08亿港元。 消息面上，石药集团宣布，已与Madrigal Pharmaceuticals,Inc.(Madrigal)就集团的口服小分子激活胰高血 糖素样肽-1(GLP-1)受体激动剂SYH2086在全球的开发、生产及商业化订立独家授权协议。根据协议条 款，集团同意授予Madrigal在全球范围内开发、生产及商业化SYH2086的独家授权，同时保留集团在中 国开发和销售其他口服小分子GLP-1受体激动剂产品的权益。集团有权收取最高可达20.75亿美元的总代 价，包括1.2亿美元的预付款、最高可达19.55亿美元的潜在开发、监管及商业里程碑付款，以及基于 SYH2086年度净销售额的高达双位数销售提成。 本文源自：智通财经网 ...

Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) rose over 5%, reaching HKD 10.62 with a trading volume of HKD 608 million, following the announcement of an exclusive licensing agreement with Madrigal Pharmaceuticals for the development, production, and commercialization of the oral GLP-1 receptor agonist SYH2086 globally [1] Group 1 - CSPC Pharmaceutical Group has entered into an exclusive licensing agreement with Madrigal Pharmaceuticals for the global development, production, and commercialization of SYH2086 [1] - Under the agreement, CSPC grants Madrigal exclusive rights to develop, produce, and commercialize SYH2086 worldwide while retaining rights to develop and sell other oral GLP-1 receptor agonist products in China [1] - CSPC is entitled to receive up to USD 2.075 billion in total consideration, which includes an upfront payment of USD 120 million, potential milestone payments of up to USD 1.955 billion, and high double-digit sales royalties based on annual net sales of SYH2086 [1]